- Home
- DRRX vs MRKR Comparison
DRRX vs MRKR Comparison
Compare DRRX & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRRX
- MRKR
- Stock Information
- Founded
- DRRX 1998
- MRKR N/A
- Country
- DRRX United States
- MRKR United States
- Employees
- DRRX N/A
- MRKR N/A
- Industry
- DRRX Biotechnology: Pharmaceutical Preparations
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- DRRX Health Care
- MRKR Health Care
- Exchange
- DRRX Nasdaq
- MRKR Nasdaq
- Market Cap
- DRRX N/A
- MRKR 19.1M
- IPO Year
- DRRX 2000
- MRKR N/A
- Fundamental
- Price
- DRRX $0.53
- MRKR $1.57
- Analyst Decision
- DRRX Hold
- MRKR Strong Buy
- Analyst Count
- DRRX 1
- MRKR 3
- Target Price
- DRRX N/A
- MRKR $13.17
- AVG Volume (30 Days)
- DRRX 46.5K
- MRKR 93.6K
- Earning Date
- DRRX 08-12-2025
- MRKR 08-13-2025
- Dividend Yield
- DRRX N/A
- MRKR N/A
- EPS Growth
- DRRX N/A
- MRKR N/A
- EPS
- DRRX N/A
- MRKR N/A
- Revenue
- DRRX $1,856,000.00
- MRKR $5,696,123.00
- Revenue This Year
- DRRX N/A
- MRKR N/A
- Revenue Next Year
- DRRX $673.00
- MRKR $11.28
- P/E Ratio
- DRRX N/A
- MRKR N/A
- Revenue Growth
- DRRX 79.84
- MRKR 71.53
- 52 Week Low
- DRRX $0.48
- MRKR $0.95
- 52 Week High
- DRRX $1.74
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- DRRX 35.42
- MRKR 51.22
- Support Level
- DRRX $0.53
- MRKR $1.56
- Resistance Level
- DRRX $0.69
- MRKR $1.93
- Average True Range (ATR)
- DRRX 0.06
- MRKR 0.11
- MACD
- DRRX -0.01
- MRKR -0.00
- Stochastic Oscillator
- DRRX 0.12
- MRKR 29.41
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.